Welcome to our dedicated page for Vtv Therapeutics news (Ticker: VTVT), a resource for investors and traders seeking the latest updates and insights on Vtv Therapeutics stock.
vTv Therapeutics Inc. (Nasdaq: VTVT) is a late-stage biopharmaceutical company focused on oral, small molecule drug candidates for diabetes and other chronic diseases. News about VTVT frequently centers on the development of its lead program, cadisegliatin (TTP399), a novel liver-selective glucokinase activator being investigated as a potential first-in-class oral adjunctive treatment to insulin for people with type 1 diabetes.
Company updates often cover key milestones in the CATT1 Phase 3 trial of cadisegliatin in adults with type 1 diabetes, including trial initiation, randomization of the first study participant, and expectations for topline data. vTv Therapeutics also issues news on its Phase 2 clinical study protocol for cadisegliatin as an adjunctive therapy to insulin in people with type 2 diabetes, developed in collaboration with M42’s Insights Research Organization & Solutions (IROS) for sites in the United Arab Emirates, Jordan, and Tunisia.
Investors following VTVT news can expect regular clinical development updates, such as preclinical and clinical data presentations at scientific meetings, including the INNODIA Symposium at the European Association for the Study of Diabetes Annual Meeting. The company also reports on intellectual property developments, including U.S. patent allowances for crystalline forms of cadisegliatin with patent terms running through 2041.
Another recurring theme in vTv Therapeutics news is financing and corporate activity, such as private placements with healthcare institutional investors and the T1D Fund intended to support the CATT1 Phase 3 trial and broader cadisegliatin program. Updates on participation in investor conferences and changes to scientific advisory structures also appear in the news flow.
For readers tracking VTVT stock, this news page aggregates company press releases and related coverage so they can monitor progress in clinical trials, regulatory interactions, patent protection, and capital-raising efforts tied to vTv Therapeutics’ diabetes-focused pipeline.
vTv Therapeutics (Nasdaq: VTVT) has secured an $80 million private placement financing from leading healthcare institutional investors and the T1D Fund. The funding will support the ongoing CATT1 Phase 3 trial of cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin for type 1 diabetes treatment.
The PIPE financing includes the sale of 682,018 shares of Class A Common Stock and pre-funded warrants for 4,561,714 shares, with accompanying warrants to purchase 5,243,732 shares. The unit price is set at $15.265 for common stock and $15.255 for pre-funded warrants, with accompanying warrants having an exercise price of $22.71 per share.
The company expects topline data from the CATT1 Phase 3 trial in the second half of 2026. The trial aims to evaluate cadisegliatin's potential in reducing hypoglycemic events and improving glycemic control in T1D patients.
vTv Therapeutics (Nasdaq: VTVT) reported Q2 2025 financial results and key developments in its cadisegliatin program for type 1 diabetes treatment. The company announced the first patient randomization in its Phase 3 CATT1 trial, with topline data expected in H2 2026. Financial results showed a net loss of $6.0 million ($0.92 per share) compared to $5.2 million ($0.81 per share) in Q2 2024.
The company's cash position stood at $25.9 million as of June 30, 2025, down from $36.7 million at year-end 2024. R&D expenses increased to $4.1 million from $3.4 million year-over-year, while G&A expenses slightly decreased to $3.6 million. Notable developments include strengthening intellectual property with a new patent allowance through 2041 and the appointment of Michael Tung as CFO.
vTv Therapeutics (Nasdaq: VTVT) has received a Notice of Allowance from the USPTO for a patent application covering crystalline forms of salts and co-crystals of cadisegliatin, their lead drug candidate. The patent, which extends through 2041, strengthens the intellectual property protection for cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin for type 1 diabetes (T1D) treatment.
The patent allowance represents a significant milestone in protecting vTv's innovative lead asset, reinforcing their commitment to developing novel therapeutic solutions.
vTv Therapeutics (Nasdaq: VTVT) has announced the randomization of its first participant in the CATT1 Phase 3 trial for cadisegliatin, a potential first-in-class oral treatment for Type 1 Diabetes (T1D). The trial will evaluate cadisegliatin as an adjunctive treatment to insulin in adults with T1D.
The study will enroll approximately 150 participants across 25 U.S. sites, testing two dose regimens (800 mg once or twice daily) against placebo. The drug, which has received FDA Breakthrough Therapy designation, has shown good tolerability in over 500 subjects. The trial's primary endpoint focuses on hypoglycemic events, with topline results expected in second half of 2026.
vTv Therapeutics (VTVT) has appointed Michael Tung, M.D., MBA as Executive Vice President and Chief Financial Officer. Dr. Tung brings 20 years of experience in finance, corporate strategy, and business development in the biopharmaceutical industry. The appointment coincides with the company's reinitiation of the CATT1 Phase 3 trial for cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin for type 1 diabetes (T1D) treatment.
Prior to joining vTv, Dr. Tung served as CFO of AdvanCell Pty Limited and held senior positions at FibroGen Inc. and Aclaris Therapeutics. He holds B.A. and B.S. degrees in economics and biology from The George Washington University and a combined M.D./M.B.A. from Tufts University School of Medicine.
vTv Therapeutics (VTVT) reported its Q4 and full-year 2024 financial results, highlighting the FDA's lifting of the clinical hold on its cadisegliatin program in March 2025. The company plans to resume its Phase 3 CATT1 trial for type 1 diabetes in Q2 2025, with a protocol amendment reducing trial duration from 12 to 6 months.
Financial highlights include a cash position of $36.7 million as of December 31, 2024, up from $9.4 million year-over-year. Q4 2024 net loss was $3.6 million ($0.55 per share), compared to $3.5 million ($1.67 per share) in Q4 2023. Full-year 2024 net loss decreased to $18.5 million ($3.20 per share) from $20.3 million in 2023.
The company strengthened its commercial leadership by appointing Martin Lafontaine as Chief Commercial Officer, bringing 27 years of pharmaceutical and medical device industry experience.
vTv Therapeutics (VTVT) announced that the FDA has lifted the clinical hold on its cadisegliatin program, including the CATT1 Phase 3 trial for type 1 diabetes (T1D). The company plans to amend the protocol to reduce the trial duration from 12 to 6 months, expediting the path to larger pivotal studies needed for NDA submission.
Cadisegliatin, an oral liver-selective glucokinase activator, aims to be the first oral adjunctive therapy to insulin for T1D. The drug has shown good tolerability in over 500 subjects with up to six months of treatment. The primary endpoint of measuring level 2 and 3 hypoglycemia rates at 6 months remains unchanged.
The clinical hold, initially placed on July 26, 2024, was due to an unresolved chromatographic signal in a human ADME study. The hold was lifted on March 14, 2025, after vTv demonstrated the signal was an experimental artifact. No patients had been dosed in the CATT1 trial during the hold period, and previous studies showed no concerning safety issues.